OIL Shares Optiscan Imaging Limited
ASX · ASXLast in our picks 2026-10-05 — not in the current list; analysis below is from that screen
Innovative imaging platform could rerate on product progress and partnerships.
Future value: $0.20 (+17.65%) · 6-12 months
Signal breakdown
- ▸Commercial and clinical catalysts remain the key rerating drivers.
- ▸Above 50-day MA (+9.47%)
- ▸Above 200-day MA — long-term uptrend
- ▸Volume 1.86× average — accumulation
- ▸Near 52-week high (75% of range) — strength
Is OIL a buy right now?
Trend: OIL is trading below the 50-day average (-6.67%), RSI 55 — neutral momentum, with a 3-month return of -3.45%.
Valuation & quality: Optiscan Imaging Limited trades on PEG 2.41, price-to-book 7.78; fundamentals show net margin -193.3%, return on equity -52.4%, revenue growth 124.5% year on year.
Our screen: STRONG BUY (score 5) — Innovative imaging platform could rerate on product progress and partnerships.
Computed from end-of-day data; not personal advice.
12-month price chart
Monthly returns
| Mar 26 | Apr 26 | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|---|---|
| +11.10% | +10.00% | +9.10% | +0.00% | +16.70% | +14.30% | -12.50% | +0.00% |
Fundamentals
Technical signals
About Optiscan Imaging Limited
Optiscan Imaging Limited engages in the development, manufacture, and commercialisation of endomicroscopic digital imaging technology solutions for medical, translational, and pre-clinical applications in Germany and the United States.
Sector: Technology · Industry: Scientific & Technical Instruments · Australia · Website
Related Biotech picks
Browse: all ASX stocks · Biotech picks · today's movers
Market data from end-of-day feeds; AI-generated research for educational purposes only — not investment advice.